行情

CRMD

CRMD

CORMEDIX
AMEX

实时行情|Nasdaq Last Sale

6.65
-0.19
-2.78%
交易中 13:15 01/28 EST
开盘
6.79
昨收
6.84
最高
6.86
最低
6.60
成交量
6.66万
成交额
--
52周最高
13.70
52周最低
4.860
市值
1.71亿
市盈率(TTM)
-4.4384
分时
5日
1月
3月
1年
5年

分析师评级

2位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

CRMD 新闻

  • Comcast: 5%+ Correction Post Q4 Results Not Justified: Reiterate Buy
  • Seeking Alpha - Article.3天前
  • Comcast -1.2% as UBS sees investments weighing growth
  • Seeking Alpha - Article.4天前
  • Here are the biggest analyst calls of the day: Alphabet, Apple, PayPal, Intel & more
  • CNBC.com.4天前
  • ClearBridge Multi Cap Growth Strategy Portfolio Manager Commentary Q4 2019
  • Seeking Alpha - Article.4天前

更多

所属板块

制药
+0.43%
制药与医学研究
+0.59%

热门股票

名称
价格
涨跌幅

CRMD 简况

CorMedix Inc. is a commercial pharmaceutical and medical device company. The Company in-licenses, develops and commercializes prophylactic and therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company has in-licensed the rights to develop and commercialize its product candidate, CRMD003 (Neutrolin), which addresses market opportunities in the instances in which a central venous catheter is used, such as hemodialysis, intensive care units, oncology, and patients receiving total parenteral nutrition, intravenous (IV) hydration, and/or IV medications. Neutrolin is an anti-infective solution for the prevention of catheter-related infections and thrombosis in the central venous catheter markets, such as dialysis, critical care and oncology. Neutrolin is a broad-spectrum antimicrobial/antifungal and anticoagulant combination that is active against common microbes, including antibiotic-resistant strains, and may prevent biofilm formation.
展开

Webull提供CorMedix Inc.的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。